Ekaterina A Laukhtina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6679685/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ex vivo study of Ho:YAG and thulium fiber lasers for soft tissue surgery: which laser for which case?. Lasers in Medical Science, 2022, 37, 149-154.	1.0	28
2	Intravesical Therapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence. European Urology Focus, 2022, 8, 447-456.	1.6	3
3	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. BJU International, 2022, 129, 182-193.	1.3	16
4	Accuracy and Clinical Utility of a Tumor Grade- and Stage-based Predictive Model in Localized Upper Tract Urothelial Carcinoma. European Urology Focus, 2022, 8, 761-768.	1.6	10
5	Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. Cancer Immunology, Immunotherapy, 2022, 71, 85-95.	2.0	6
6	Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. European Urology Focus, 2022, 8, 752-760.	1.6	8
7	Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers. World Journal of Urology, 2022, 40, 1317-1323.	1.2	8
8	Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow-up. Minerva Urology and Nephrology, 2022, 74, .	1.3	7
9	Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. Minerva Urology and Nephrology, 2022, 74, .	1.3	2
10	The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials. European Urology Oncology, 2022, 5, 138-145.	2.6	6
11	Systemic therapies for metastatic hormoneâ€sensitive prostate cancer: network metaâ€analysis. BJU International, 2022, 129, 423-433.	1.3	37
12	Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. European Urology Focus, 2022, 8, 1270-1277.	1.6	11
13	Choosing the Most Efficacious and Safe Oral Treatment for Idiopathic Overactive Bladder: A Systematic Review and Network Meta-analysis. European Urology Focus, 2022, 8, 1072-1089.	1.6	14
14	Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Molecular Carcinogenesis, 2022, 61, 5-18.	1.3	6
15	Comparison of Clinicopathologic and Oncological Outcomes Between Transurethral En Bloc Resection and Conventional Transurethral Resection of Bladder Tumor: A Systematic Review, Meta-Analysis, and Network Meta-Analysis with Focus on Different Energy Sources. Journal of Endourology 2022 36 535-547	1.1	11
16	Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 95.e1-95.e6.	0.9	20
17	Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach. World Journal of Urology, 2022, 40, 747-754.	1.2	4
18	Impact of preoperative systemic immune-inflammation Index on oncologic outcomes in bladder cancer patients treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 106.e11-106.e19.	0.8	14

#	Article	IF	CITATIONS
19	Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2022, 27, 59-71.	1.0	19
20	Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Clinical Genitourinary Cancer, 2022, 20, 227-236.	0.9	3
21	Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 3091-3102.	1.2	2
22	Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Critical Reviews in Oncology/Hematology, 2022, 169, 103570.	2.0	11
23	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Minerva Urology and Nephrology, 2022, 74, .	1.3	8
24	The Value of Preoperative Plasma VEGF Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. European Urology Focus, 2022, 8, 972-979.	1.6	3
25	<i>En Bloc</i> Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. Journal of Urology, 2022, 207, 754-768.	0.2	26
26	Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. European Urology Oncology, 2022, 5, 120-124.	2.6	6
27	Comparison of short-term and long-term neoadjuvant hormone therapy prior to radical prostatectomy: a systematic review and meta-analysis. Scandinavian Journal of Urology, 2022, 56, 85-93.	0.6	3
28	Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis. Cancers, 2022, 14, 887.	1.7	12
29	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. World Journal of Urology, 2022, 40, 1167-1174.	1.2	9
30	Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e11-273.e20.	0.8	8
31	Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors. European Urology Oncology, 2022, 5, 30-41.	2.6	11
32	Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. Arab Journal of Urology Arab Association of Urology, 2022, 20, 71-80.	0.7	2
33	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	1.2	0
34	Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Annals of Surgical Oncology, 2022, 29, 5307-5316.	0.7	6
35	Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers, 2022, 14, 1781.	1.7	1
36	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology—Young Academic Urologists: Urothelial Carcinoma Working Group. European Urology Focus, 2022, 8, 1635-1642.	1.6	7

#	Article	IF	CITATIONS
37	Systematic Review: The Learning Curve for Robot-Assisted Radical Cystectomy—What Do We Know?. Journal of Endourology, 2022, , .	1.1	9
38	Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis. European Urology Focus, 2022, 8, 1687-1695.	1.6	10
39	Prognostic impact of insulinâ€like growth factorâ€l and its binding proteins, insulinâ€like growth factorâ€l binding proteinâ€2 and â€3, on adverse histopathological features and survival outcomes after radical cystectomy. International Journal of Urology, 2022, , .	0.5	3
40	Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study. European Urology Open Science, 2022, 39, 14-21.	0.2	7
41	The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis. International Immunopharmacology, 2022, 108, 108720.	1.7	13
42	The placebo and nocebo effects in functional urology. Nature Reviews Urology, 2022, 19, 171-189.	1.9	5
43	Influence of steep Trendelenburg position on postoperative complications: a systematic review and meta-analysis. Journal of Robotic Surgery, 2022, 16, 1233-1247.	1.0	6
44	The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer. Cancers, 2022, 14, 1613.	1.7	4
45	Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis. Prostate Cancer and Prostatic Diseases, 2022, 25, 187-198.	2.0	7
46	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	0.9	15
47	Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy, 2022, 14, 709-725.	1.0	10
48	Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Translational Cancer Research, 2022, 11, 908-917.	0.4	2
49	Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. European Urology, 2022, ,	0.9	2
50	ASO Visual Abstract: Prognostic Role of Preoperative Vascular Cell Adhesion Molecule-1 Plasma Levels in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. Annals of Surgical Oncology, 2022, , 1.	0.7	0
51	Differential efficacy of ablation therapy versus partial nephrectomy between clinical T1a and T1b renal tumors: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 315-330.	0.8	15
52	Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma. European Urology Focus, 2022, 8, 1683-1686.	1.6	4
53	The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy. European Urology Open Science, 2022, 41, 74-80.	0.2	2
54	The Impact of Surgical Waiting Time on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy: A Systematic Review. Journal of Clinical Medicine, 2022, 11, 4007.	1.0	3

Ekaterina A Laukhtina

#	Article	IF	CITATIONS
55	How Lasers Ablate Stones: <i>In Vitro</i> Study of Laser Lithotripsy (Ho:YAG and Tm-Fiber Lasers) in Different Environments. Journal of Endourology, 2021, 35, 931-936.	1.1	39
56	Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis. World Journal of Urology, 2021, 39, 1757-1768.	1.2	20
57	Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis. European Urology Focus, 2021, 7, 1143-1156.	1.6	6
58	The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and metaâ€analysis. BJU International, 2021, 127, 143-152.	1.3	5
59	The impact of the laser fiber-tissue distance on histological parameters in a porcine kidney model. World Journal of Urology, 2021, 39, 1607-1612.	1.2	15
60	Primary Ta high grade bladder tumors: Determination of the risk of progression. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 132.e7-132.e11.	0.8	9
61	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 235.e5-235.e14.	0.8	8
62	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2021, 51, 1149-1157.	0.6	4
63	Further Understanding of Urokinase Plasminogen Activator Overexpression in Urothelial Bladder Cancer Progression, Clinical Outcomes and Potential Therapeutic Targets. OncoTargets and Therapy, 2021, Volume 14, 315-324.	1.0	5
64	Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer. World Journal of Urology, 2021, 39, 3345-3352.	1.2	18
65	The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. Journal of Urology, 2021, 205, 60-67.	0.2	36
66	Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma. Turkish Journal of Urology, 2021, 47, S33-S44.	1.3	1
67	Prognostic role of the systemic immune–inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. Cancer Immunology, Immunotherapy, 2021, 70, 2641-2650.	2.0	21
68	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Translational Andrology and Urology, 2021, 10, 609-619.	0.6	5
69	Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method. Journal of Clinical Medicine, 2021, 10, 1055.	1.0	1
70	Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 180-190.	0.8	10
71	First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 755-765.	2.6	100
72	Penile Rehabilitation Strategy after Nerve Sparing Radical Prostatectomy: A Systematic Review and Network Meta-Analysis of Randomized Trials. Journal of Urology, 2021, 205, 1018-1030.	0.2	27

#	Article	IF	CITATIONS
73	Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. European Urology, 2021, 80, 549-563.	0.9	53
74	Association between male infertility and prostate cancer: a systematic review and meta-analysis. Current Opinion in Urology, 2021, 31, 346-353.	0.9	3
75	Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. World Journal of Urology, 2021, 39, 4085-4099.	1.2	9
76	Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of nonâ€muscleâ€invasive bladder cancer: a systematic review and network metaâ€analysis of randomized trials. BJU International, 2021, 128, 280-289.	1.3	17
77	The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. Prostate, 2021, 81, 765-771.	1.2	4
78	The prognostic value of sarcopenia in patients with prostate cancer: a systematic review. Current Opinion in Urology, 2021, 31, 315-323.	0.9	7
79	Role of systemic immune-inflammation index in patients treated with salvage radical prostatectomy. World Journal of Urology, 2021, 39, 3771-3779.	1.2	10
80	Differential prognostic impact of different Gleason patterns in grade group 4 in radical prostatectomy specimens. European Journal of Surgical Oncology, 2021, 47, 1172-1178.	0.5	7
81	Prognostic Impact of Different Cleason Patterns on Biopsy Within Grade Group 4 Prostate Cancer. Annals of Surgical Oncology, 2021, 28, 9179-9187.	0.7	3
82	Intracorporeal versus extracorporeal urinary diversion in robot-assisted radical cystectomy: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2021, 26, 1587-1599.	1.0	16
83	Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy. Journal of Urology, 2021, 206, 1122-1131.	0.2	5
84	Impact of systemic Immune–inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 785.e19-785.e27.	0.8	14
85	Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer. World Journal of Urology, 2021, 39, 4355-4361.	1.2	18
86	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. International Journal of Clinical Oncology, 2021, 26, 1729-1735.	1.0	3
87	Incidence, risk factors and outcomes of urethral recurrence after radical cystectomy for bladder cancer: A systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 806-815.	0.8	7
88	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. European Journal of Cancer, 2021, 151, 35-48.	1.3	24
89	Adjuvant therapy with tyrosine kinase inhibitors for localized and locally advanced renal cell carcinoma: an updated systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 764-773.	0.8	14
90	Adverse events of the second-line treatment for patients with locally advanced or metastatic urothelial carcinoma of the bladder: network meta-analysis. Immunotherapy, 2021, 13, 917-929.	1.0	1

#	Article	IF	CITATIONS
91	Prognostic blood-based biomarkers in patients treated with neoadjuvant chemotherapy for urothelial carcinoma of the bladder: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 471-479.	0.8	7
92	The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 4197.	1.0	16
93	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 99, 102242.	3.4	13
94	Adverse events of different chemotherapy regimens in the first-line treatment of patients with advanced or metastatic urothelial cancer: A systematic review and network meta-analysis of randomized controlled trials. Seminars in Oncology, 2021, 48, 181-192.	0.8	2
95	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	1.2	3
96	Expression Analysis and Mutational Status of Histone Methyltransferase KMT2D at Different Upper Tract Urothelial Carcinoma Locations. Journal of Personalized Medicine, 2021, 11, 1147.	1.1	1
97	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	2.6	40
98	Reply to Laurence Klotz's Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels―in Major Urology Meetings. Eur Urol 2021;80:442–9. Eur Urol 2021;80:e100. European Urology, 2021, 81, e26-e26.	0.9	1
99	Evaluation of the Predictive Role of Blood-Based Biomarkers in the Context of Suspicious Prostate MRI in Patients Undergoing Prostate Biopsy. Journal of Personalized Medicine, 2021, 11, 1231.	1.1	5
100	Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. Minerva Urology and Nephrology, 2021, 73, 610-615.	1.3	6
101	Association of statins use and mortality outcomes in prostate cancer patients who received androgen deprivation therapy: a systematic review and meta-analysis. Central European Journal of Urology, 2021, 74, 484-490.	0.2	2
102	A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. Minerva Urology and Nephrology, 2021, , .	1.3	4
103	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. Minerva Urology and Nephrology, 2021, , .	1.3	8
104	Monopolar enucleation versus transurethral resection of the prostate for small- and medium-sized (< 80Âcc) benign prostate hyperplasia: a prospective analysis. World Journal of Urology, 2020, 38, 167-173.	1.2	8
105	Ex vivo and animal study of the blue diode laser, Tm fiber laser, and their combination for laparoscopic partial nephrectomy. Lasers in Surgery and Medicine, 2020, 52, 437-448.	1.1	16
106	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 936.e7-936.e14.	0.8	3
107	Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit. Journal of Clinical Medicine, 2020, 9, 3306.	1.0	4
108	Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1881-1891.	1.0	8

#	Article	IF	CITATIONS
109	Delaying BCG immunotherapy onset after transurethral resection of non-muscle-invasive bladder cancer is associated with adverse survival outcomes. World Journal of Urology, 2020, 39, 2545-2552.	1.2	16
110	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1892-1900.	1.0	45
111	Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC). World Journal of Urology, 2020, 39, 1961-1968.	1.2	10
112	Prognostic models to help predict patient responses to intravesical immunotherapy. Expert Review of Precision Medicine and Drug Development, 2020, 5, 243-251.	0.4	1
113	Dual-Energy Computed Tomography for Stone Type Assessment: A Pilot Study of Dual-Energy Computed Tomography with Five Indices. Journal of Endourology, 2020, 34, 893-899.	1.1	8
114	Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. International Journal of Clinical Oncology, 2020, 25, 1037-1054.	1.0	31
115	Long-Term Outcomes of Holmium Laser Enucleation of the Prostate: A 5-Year Single-Center Experience. Journal of Endourology, 2020, 34, 1055-1063.	1.1	13
116	Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 774-782.	0.8	26
117	Temperature changes during laser lithotripsy with Ho:YAG laser and novel Tm-fiber laser: a comparative in-vitro study. World Journal of Urology, 2020, 38, 3261-3266.	1.2	48
118	Comparative Analysis of Vaporization and Coagulation Properties of a Hybrid Laser (Combination of a) Tj ETQqO Endoscopic Enucleation of the Prostate. Journal of Endourology, 2020, 34, 862-867.	0 0 rgBT /0 1.1	Overlock 101 12
119	Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. Current Opinion in Urology, 2020, 30, 457-466.	0.9	2
120	Catalog of exogenous risk factors for bladder carcinogenesis. Current Opinion in Urology, 2020, 30, 449-456.	0.9	14
121	The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 204, 909-917.	0.2	21
122	En bloc and two-lobe techniques for laser endoscopic enucleation of the prostate: retrospective comparative analysis of peri- and postoperative outcomes. International Urology and Nephrology, 2019, 51, 1969-1974.	0.6	24
123	Novel thulium fiber laser for endoscopic enucleation of the prostate: A prospective comparison with conventional transurethral resection of the prostate. International Journal of Urology, 2019, 26, 1138-1143.	0.5	35
124	Impact of endoscopic enucleation of the prostate with thulium fiber laser on the erectile function. BMC Urology, 2018, 18, 87.	0.6	36
125	Need for upper urinary tract stenting in cases of ureteral orifice injury during laser enucleation of the prostate. International Urology and Nephrology, 2018, 50, 2173-2177.	0.6	13
126	The evolution of lasers in urology Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, 0, , .	0.2	1

#	Article	IF	CITATIONS
127	Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study. World Journal of Urology, 0, , .	1.2	3